ArticleClinical ophthalmology (Auckland, N.Z.)2022
Psychosocial Impact of
Article in Clinical ophthalmology (Auckland, N.Z.), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 30 citations in OpenAlex.
- Trial
- Intense pulsed light as a multi-target intervention paradigm for refractory ocular surface diseases: a review.Eye and vision (London, England) · 2026Review
- Ivermectin in the Management of Demodex -associated Blepharitis: A Comprehensive Literature Review.Eye & contact lens · 2026Review
- [Demodex blepharitis-The downward gaze in the slit lamp].Die Ophthalmologie · 2026Article
- Proportion of patients with Demodex blepharitis in ophthalmology clinics in Europe: the Eos study.Eye (London, England) · 2026Article
- An Observational, Multicenter, Parallel-Cohort Study Evaluating the Association of Clinical Manifestations and Patient-Reported Outcomes in Patients withClinical optometry · 2026Article
- Using Lotilaner Ophthalmic Solution, 0.25% to TreatClinical optometry · 2026Article
- Lotilaner ophthalmic solution 0.25% in the treatment ofSAGE open medical case reports · 2026Article
- Effects of Lotilaner Ophthalmic Solution, 0.25% onClinical ophthalmology (Auckland, N.Z.) · 2026Article
- Pharmacotherapy ofPharmacy (Basel, Switzerland) · 2025Article
- Significance ofMedicina (Kaunas, Lithuania) · 2025Review
- Safety and Efficacy of Lotilaner Ophthalmic Solution (0.25%) in Treating Demodex Blepharitis: Pooled Analysis of Two Pivotal Trials.Ophthalmology and therapy · 2025Article
- Demodex and the eye - A review.Indian journal of ophthalmology · 2025Review
- Patient-Reported Burden of Illness and Unmet Needs inPatient preference and adherence · 2025Article
- TheClinical ophthalmology (Auckland, N.Z.) · 2025Article
- Intense Pulsed Light Combined with Low Level Blue and Red Light Therapy forClinical ophthalmology (Auckland, N.Z.) · 2025Article
- Efficacy of 1% Povidone-Iodine in the Treatment of Anterior Blepharitis-Randomized Single-Center Controlled Trial.Journal of clinical medicine · 2024Article
- Multidisciplinary perspectives inJournal of managed care & specialty pharmacy · 2024Review
- The Prevalence ofLife (Basel, Switzerland) · 2024Article
- Lotilaner Ophthalmic Solution, 0.25%, for the Treatment ofHealthcare (Basel, Switzerland) · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To evaluate the impact of Patients and Methods: In this multicenter, observational, prospective, IRB-approved study, 311 Results: More than half the patients had been experiencing symptoms of blepharitis for ≥4 years. The three most frequent and bothersome symptoms experienced by patients were dry eyes, itchiness, and irritation. Nearly half the patients (47%) responded that they were conscious of their eyes all day, and 23% said that they were constantly worrying about their eyes. Other activities that were negatively affected included difficulty driving at night (47%), additional time needed for daily hygiene routine (30%), and difficulty in wearing eye make-up (in 34% of females). While all subjects had objective signs of Conclusion:
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.